Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy

OncoImmunology

Volumn 4, Issue 8, 2015, Pages

  Van Acker, Heleen H ^a   Anguille, Sébastien ^a,b   Van Tendeloo, Viggo F ^a   Lion, Eva ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

cancer; DC mediated T cell activation; dendritic cell; immunotherapy; T cell

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PAMIDRONIC ACID; PROSTAGLANDIN E2; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXICITY ASSAY; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNOMODULATION; IMMUNOPHENOTYPING; NEOPLASM; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 84939144984     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1021538     Document Type: Article

References (79)

1. P.Vantourout, A.Hayday. Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol 2013; 13:88-100; PMID:23348415; http://dx.doi.org/10.1038/nri3384
2. A.C.Hayday. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 2009; 31:184-96; PMID:19699170; http://dx.doi.org/10.1016/j.immuni.2009.08.006
3. W.K.Born, M.Kemal Aydintug, R.L.O'Brien. Diversity of gammadelta T-cell antigens. Cell Mol Immunol 2013; 10:13-20; PMID:23085946; http://dx.doi.org/10.1038/cmi.2012.45
4. M.S.Braza, B.Klein. Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside. Br J Haematol 2013; 160:123-32; PMID:23061882; http://dx.doi.org/10.1111/bjh.12090
5. J.P.Fisher, J.Heuijerjans, M.Yan, K.Gustafsson, J.Anderson. gammadelta T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology 2014; 3:e27572; PMID:24734216; http://dx.doi.org/10.4161/onci.27572
6. S.Anguille, E.L.Smits, E.Lion, V.F.van Tendeloo, Z.N.Berneman. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-e67; PMID:24872109; http://dx.doi.org/10.1016/S1470-2045(13)70585-0
7. M.Fajardo-Moser, S.Berzel, H.Moll. Mechanisms of dendritic cell-based vaccination against infection. Intl J Med Microbiol 2008; 298:11-20; PMID:17719274; http://dx.doi.org/10.1016/j.ijmm.2007.07.003
8. E.Van Gulck, E.Vlieghe, M.Vekemans, V.F.Van Tendeloo, A.Van De Velde, E.Smits, S.Anguille, N.Cools, H.Goossens, L.Mertens et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 2012; 26:F1-12; PMID:22156965; http://dx.doi.org/10.1097/QAD.0b013e32834f33e8
9. C.Massa, B.Seliger. Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities. J Immunol 2013; 190:3328-37; PMID:23447683; http://dx.doi.org/10.4049/jimmunol.1202024
10. G.Gruenbacher, H.Gander, A.Rahm, W.Nussbaumer, N.Romani, M.Thurnher. CD56+ human blood dendritic cells effectively promote TH1-type gammadelta T-cell responses. Blood 2009; 114:4422-31; PMID:19762486; http://dx.doi.org/10.1182/blood-2009-06-227256
11. L.M.Ferreira. Gammadelta T cells: innately adaptive immune cells? Int Rev Immunol 2013; 32:223-48; PMID:23617235; http://dx.doi.org/10.3109/08830185.2013.783831
12. B.S.Sheridan, P.A.Romagnoli, Q.M.Pham, H.H.Fu, F.Alonzo, III, W.D.Schubert, N.E.Freitag, L.Lefrancois. gammadelta T cells exhibit multifunctional and protective memory in intestinal tissues. Immunity 2013; 39:184-95; PMID:23890071; http://dx.doi.org/10.1016/j.immuni.2013.06.015
13. J.M.Jameson, J.Cruz, A.Costanzo, M.Terajima, F.A.Ennis. A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes. Cell Immunol 2010; 264:71-7; PMID:20483407; http://dx.doi.org/10.1016/j.cellimm.2010.04.013
14. J.Zheng, Y.Liu, Y.L.Lau, W.Tu. gammadelta-T cells: an unpolished sword in human anti-infection immunity. Cell Mol Immunol 2013; 10:50-7; PMID:23064104; http://dx.doi.org/10.1038/cmi.2012.43
15. C.T.Morita, C.Jin, G.Sarikonda, H.Wang. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev 2007; 215:59-76; PMID:17291279; http://dx.doi.org/10.1111/j.1600-065X.2006.00479.x
16. J.M.Aswald, X.H.Wang, S.Aswald, A.Lutynski, M.D.Minden, H.A.Messner, A.Keating. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? Cytometry B Clin Cytom 2006; 70:379-90; PMID:16977635; http://dx.doi.org/10.1002/cyto.b.20115
17. T.Yuasa, K.Sato, E.Ashihara, M.Takeuchi, S.Maita, N.Tsuchiya, T.Habuchi, T.Maekawa, S.Kimura. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 2009; 58:493-502; PMID:18682944; http://dx.doi.org/10.1007/s00262-008-0571-9
18. M.Todaro, M.D'Asaro, N.Caccamo, F.Iovino, M.G.Francipane, S.Meraviglia, V.Orlando, C.La Mendola, G.Gulotta, A.Salerno et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009; 182:7287-96; PMID:19454726; http://dx.doi.org/10.4049/jimmunol.0804288
19. N.L.Bryant, C.Suarez-Cuervo, G.Y.Gillespie, J.M.Markert, L.B.Nabors, S.Meleth, R.D.Lopez, L.S.LambJr. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro Oncol 2009; 11:357-67; PMID:19211933; http://dx.doi.org/10.1215/15228517-2008-111
20. J.Rey, C.Veuillen, N.Vey, R.Bouabdallah, D.Olive. Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors. Trends Mol Med 2009; 15:275-84; PMID:19487160; http://dx.doi.org/10.1016/j.molmed.2009.04.005
21. A.Knight, S.Mackinnon, M.W.Lowdell. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 2012; 14:1110-8; PMID:22800570; http://dx.doi.org/10.3109/14653249.2012.700766
22. S.Meraviglia, M.Eberl, D.Vermijlen, M.Todaro, S.Buccheri, G.Cicero, C.La Mendola, G.Guggino, M.D'Asaro, V.Orlando et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010; 161:290-7; PMID:20491785
23. M.Naoe, Y.Ogawa, K.Takeshita, J.Morita, T.Shichijo, K.Fuji, T.Fukagai, S.Iwamoto, S.Terao. Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res 2010; 18:493-501; PMID:20681408; http://dx.doi.org/10.3727/096504010X12671222663638
24. K.T.Godder, P.J.Henslee-Downey, J.Mehta, B.S.Park, K.Y.Chiang, S.Abhyankar, L.S.Lamb. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplan 2007; 39:751-7; PMID:17450185; http://dx.doi.org/10.1038/sj.bmt.1705650
25. S.Kalyan, D.Kabelitz. Defining the nature of human gammadelta T cells: a biographical sketch of the highly empathetic. Cell Mol Immunol 2013; 10:21-9; PMID:23085947; http://dx.doi.org/10.1038/cmi.2012.44
26. A.Thedrez, C.Sabourin, J.Gertner, M.C.Devilder, S.Allain-Maillet, J.J.Fournie, E.Scotet, M.Bonneville. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev 2007; 215:123-35; PMID:17291284; http://dx.doi.org/10.1111/j.1600-065X.2006.00468.x
27. O.Toutirais, F.Cabillic, G.Le Friec, S.Salot, P.Loyer, M.Le Gallo, M.Desille, C.T.de La Pintiere, P.Daniel, F.Bouet et al. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells. EurJ Immunol 2009; 39:1361-8; PMID:19404979; http://dx.doi.org/10.1002/eji.200838409
28. S.Beetz, L.Marischen, D.Kabelitz, D.Wesch. Human gamma delta T cells: candidates for the development of immunotherapeutic strategies. Immunol Res 2007; 37:97-111; PMID:17695246; http://dx.doi.org/10.1007/BF02685893
29. M.Brandes, K.Willimann, B.Moser. Professional antigen-presentation function by human gammadelta T Cells. Science 2005; 309:264-8; PMID:15933162; http://dx.doi.org/10.1126/science.1110267
30. B.Moser, M.Eberl. gammadelta T-APCs: a novel tool for immunotherapy? Cell Mol Life Sci 2011; 68:2443-52; PMID:21573785; http://dx.doi.org/10.1007/s00018-011-0706-6
31. A.H.Capietto, L.Martinet, J.J.Fournie. How tumors might withstand gammadelta T-cell attack. Cell Mol Life Sci 2011; 68:2433-42; PMID:21547501; http://dx.doi.org/10.1007/s00018-011-0705-7
32. L.Martinet, R.Poupot, J.J.Fournie. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies. Immunol Lett 2009; 124:1-8; PMID:19465238; http://dx.doi.org/10.1016/j.imlet.2009.03.011
33. J.Ye, C.Ma, E.C.Hsueh, C.S.Eickhoff, Y.Zhang, M.A.Varvares, D.F.Hoft, G.Peng. Tumor-derived gammadelta regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol 2013; 190:2403-14; PMID:23355732; http://dx.doi.org/10.4049/jimmunol.1202369
34. J.Ye, C.Ma, F.Wang, E.C.Hsueh, K.Toth, Y.Huang, W.Mo, S.Liu, B.Han, M.A.Varvares et al. Specific recruitment of gammadelta regulatory T cells in human breast cancer. Cancer Res 2013; 73:6137-48; PMID:23959855; http://dx.doi.org/10.1158/0008-5472.CAN-13-0348
35. Y.Yi, H.W.He, J.X.Wang, X.Y.Cai, Y.W.Li, J.Zhou, Y.F.Cheng, J.J.Jin, J.Fan, S.J.Qiu. The functional impairment of HCC-infiltrating gammadelta T cells, partially mediated by regulatory T cells in a TGFbeta- and IL-10-dependent manner. J Hepatol 2013; 58:977-83; PMID:23262246; http://dx.doi.org/10.1016/j.jhep.2012.12.015
36. A.Gaafar, M.D.Aljurf, A.Al-Sulaiman, A.Iqniebi, P.S.Manogaran, G.E.Mohamed, A.Al-Sayed, H.Alzahrani, F.Alsharif, F.Mohareb et al. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol 2009; 37:838-48; PMID:19446661; http://dx.doi.org/10.1016/j.exphem.2009.04.003
37. M.Ni, D.Martire, E.Scotet, M.Bonneville, F.Sanchez, V.Lafont. Full restoration of Brucella-infected dendritic cell functionality through Vgamma9Vdelta2 T helper type 1 crosstalk. PloS One 2012; 7:e43613
38. M.R.Dunne, L.Madrigal-Estebas, L.M.Tobin, D.G.Doherty. (E)-4-hydroxy-3-methyl-but-2 enyl pyrophosphate-stimulated Vgamma9Vdelta2 T cells possess T helper type 1-promoting adjuvant activity for human monocyte-derived dendritic cells. Cancer Immunol Immunother 2010; 59:1109-20; PMID:20306041; http://dx.doi.org/10.1007/s00262-010-0839-8
39. A.Martino, F.Poccia. Gamma delta T cells and dendritic cells: close partners and biological adjuvants for new therapies. Curr Mol Med 2007; 7:658-73; PMID:18045144; http://dx.doi.org/10.2174/156652407782564345
40. R.Casetti, A.Martino. The plasticity of gamma delta T cells: innate immunity, antigen presentation and new immunotherapy. Cell Mol Immunol 2008; 5:161-70; PMID:18582397; http://dx.doi.org/10.1038/cmi.2008.20
41. M.Takamizawa, F.Fagnoni, A.Mehta-Damani, A.Rivas, E.G.Engleman. Cellular and molecular basis of human gamma delta T cell activation. Role of accessory molecules in alloactivation. J Clin Invest 1995; 95:296-303; PMID:7814628; http://dx.doi.org/10.1172/JCI117654
42. Z.Ye, S.Haley, A.P.Gee, P.J.Henslee-Downey, L.S.Lamb, Jr. In vitro interactions between gamma deltaT cells, DC, and CD4+ T cells; implications for the immunotherapy of leukemia. Cytotherapy 2002; 4:293-304; PMID:12194726; http://dx.doi.org/10.1080/146532402320219817
43. M.C.Devilder, S.Maillet, I.Bouyge-Moreau, E.Donnadieu, M.Bonneville, E.Scotet. Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J Immunol 2006; 176:1386-93; PMID:16424165; http://dx.doi.org/10.4049/jimmunol.176.3.1386
44. F.Fiore, B.Castella, B.Nuschak, R.Bertieri, S.Mariani, B.Bruno, F.Pantaleoni, M.Foglietta, M.Boccadoro, M.Massaia. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007; 110:921-7; PMID:17403919; http://dx.doi.org/10.1182/blood-2006-09-044321
45. H.J.Gober, M.Kistowska, L.Angman, P.Jeno, L.Mori, G.De Libero. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197:163-8; PMID:12538656; http://dx.doi.org/10.1084/jem.20021500
46. V.Kunzmann, E.Bauer, J.Feurle, F.Weissinger, H.P.Tony, M.Wilhelm. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96:384-92; PMID:10887096
47. N.Soriano-Sarabia, H.Sandvold, H.Jomaa, T.Kubin, G.Bein, H.Hackstein. Primary MHC-class II(+) cells are necessary to promote resting Vdelta2 cell expansion in response to (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate and isopentenyl pyrophosphate. J Immunol 2012; 189:5212-22; PMID:23105138; http://dx.doi.org/10.4049/jimmunol.1200093
48. A.Martino, R.Casetti, A.Sacchi, F.Poccia. Central memory Vgamma9Vdelta2 T lymphocytes primed and expanded by bacillus Calmette-Guerin-infected dendritic cells kill mycobacterial-infected monocytes. J Immunol 2007; 179:3057-64; PMID:17709520; http://dx.doi.org/10.4049/jimmunol.179.5.3057
49. S.Meraviglia, N.Caccamo, A.Salerno, G.Sireci, F.Dieli. Partial and ineffective activation of V gamma 9V delta 2 T cells by Mycobacterium tuberculosis-infected dendritic cells. J Immunol 2010; 185:1770-6; PMID:20592281; http://dx.doi.org/10.4049/jimmunol.1000966
50. A.Sacchi, A.Rinaldi, N.Tumino, R.Casetti, C.Agrati, F.Turchi, V.Bordoni, E.Cimini, F.Martini. HIV infection of monocytes-derived dendritic cells inhibits Vgamma9Vdelta2 T cells functions. PloS One 2014; 9:e111095; PMID:25340508; http://dx.doi.org/10.1371/journal.pone.0111095
51. M.von Lilienfeld-Toal, E.Sievers, V.Bodemuller, C.Mihailescu, A.Marten, M.Gorschluter, I.G.Schmidt-Wolf. Coculture with dendritic cells promotes proliferation but not cytotoxic activity of gamma/delta T cells. Immunol Lett 2005; 99:103-8; PMID:15894118; http://dx.doi.org/10.1016/j.imlet.2005.02.001
52. J.M.Van den Bergh, V.F.Van Tendeloo, E.L.Smits. Interleukin-15: New kid on the block for antitumor combination therapy. Cytokine Growth Factor Rev 2014; 26(1):15-24; PMID:25306466; http://dx.doi.org/10.1016/j.cytogfr.2014.09.001
53. N.Caccamo, S.Meraviglia, V.Ferlazzo, D.Angelini, G.Borsellino, F.Poccia, L.Battistini, F.Dieli, A.Salerno. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur J Immunol 2005; 35:1764-72; PMID:15915537; http://dx.doi.org/10.1002/eji.200525983
54. K.M.Harris. Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J Leukocyte Biol 2011; 90:727-34; PMID:21724805; http://dx.doi.org/10.1189/jlb.0311132
55. S.Anguille, E.Lion, J.Van den Bergh, H.H.Van Acker, Y.Willemen, E.L.Smits, V.F.Van Tendeloo, Z.N.Berneman. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum Vaccin Immunother 2013; 9:1956-61; PMID:23778748; http://dx.doi.org/10.4161/hv.25373
56. S.Anguille, E.L.Smits, N.Cools, H.Goossens, Z.N.Berneman, V.F.Van Tendeloo. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 2009; 7:109; PMID:20021667; http://dx.doi.org/10.1186/1479-5876-7-109
57. P.Dubsky, H.Saito, M.Leogier, C.Dantin, J.E.Connolly, J.Banchereau, A.K.Palucka. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol 2007; 37:1678-90; PMID:17492620; http://dx.doi.org/10.1002/eji.200636329
58. H.Jonuleit, U.Kuhn, G.Muller, K.Steinbrink, L.Paragnik, E.Schmitt, J.Knop, A.H.Enk. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27:3135-42; PMID:9464798; http://dx.doi.org/10.1002/eji.1830271209
59. N.Shrestha, J.A.Ida, A.S.Lubinski, M.Pallin, G.Kaplan, P.A.Haslett. Regulation of acquired immunity by gamma delta T-cell/dendritic-cell interactions. Ann N Y Acad Sci 2005; 1062:79-94; PMID:16461791; http://dx.doi.org/10.1196/annals.1358.011
60. M.C.Devilder, S.Allain, C.Dousset, M.Bonneville, E.Scotet. Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells. J Immunol 2009; 183:3625-33; PMID:19710464; http://dx.doi.org/10.4049/jimmunol.0901571
61. V.Kunzmann, E.Kretzschmar, T.Herrmann, M.Wilhelm. Polyinosinic-polycytidylic acid-mediated stimulation of human gammadelta T cells via CD11c dendritic cell-derived type I interferons. Immunology 2004; 112:369-77; PMID:15196204; http://dx.doi.org/10.1111/j.1365-2567.2004.01908.x
62. Y.Ma, L.Aymeric, C.Locher, S.R.Mattarollo, N.F.Delahaye, P.Pereira, L.Boucontet, L.Apetoh, F.Ghiringhelli, N.Casares et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208:491-503; PMID:21383056; http://dx.doi.org/10.1084/jem.20100269
63. D.Wakita, K.Sumida, Y.Iwakura, H.Nishikawa, T.Ohkuri, K.Chamoto, H.Kitamura, T.Nishimura. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. EurJ Immunol 2010; 40:1927-37; PMID:20397212; http://dx.doi.org/10.1002/eji.200940157
64. V.Kunzmann, M.Smetak, B.Kimmel, K.Weigang-Koehler, M.Goebeler, J.Birkmann, J.Becker, I.G.Schmidt-Wolf, H.Einsele, M.Wilhelm. Tumor-promoting versus tumor-antagonizing roles of gammadelta T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother 2012; 35:205-13; PMID:22306909; http://dx.doi.org/10.1097/CJI.0b013e318245bb1e
65. M.Nieda, H.Terunuma, Y.Eiraku, X.Deng, A.J.Nicol. Effective induction of melanoma-antigen-specific CD8+ T cells via Vgamma9gammadeltaT cell-expansion by CD56 Interferon-alpha-induced dendritic cells. Exp Dermatol 2014; 24(1):35-41; PMID:25363560; http://dx.doi.org/10.1111/exd.12581
66. M.Takahara, M.Miyai, M.Tomiyama, M.Mutou, A.J.Nicol, M.Nieda. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation. J Leukocyte Biol 2008; 83:742-54; PMID:18156189; http://dx.doi.org/10.1189/jlb.0307185
67. M.W.Traxlmayr, D.Wesch, A.M.Dohnal, P.Funovics, M.B.Fischer, D.Kabelitz, T.Felzmann. Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. J Immunother 2010; 33:40-52; PMID:19952957; http://dx.doi.org/10.1097/CJI.0b013e3181b51447
68. F.Cabillic, O.Toutirais, V.Lavoue, C.T.de La Pintiere, P.Daniel, N.Rioux-Leclerc, B.Turlin, H.Monkkonen, J.Monkkonen, K.Boudjema et al. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother 2010; 59:1611-9; PMID:20582413; http://dx.doi.org/10.1007/s00262-010-0887-0
69. B.Castella, C.Riganti, F.Fiore, F.Pantaleoni, M.E.Canepari, S.Peola, M.Foglietta, A.Palumbo, A.Bosia, M.Coscia et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vgamma9Vdelta2 T cells, alphabeta CD8+ T cells, regulatory T cells, and dendritic cells. J Immunol 2011; 187:1578-90; PMID:21753152; http://dx.doi.org/10.4049/jimmunol.1002514
70. K.Thompson, M.J.Rogers. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004; 19:278-88; PMID:14969398; http://dx.doi.org/10.1359/JBMR.0301230
71. D.W.Fowler, J.Copier, A.G.Dalgleish, M.D.Bodman-Smith. Tripartite immune cell co-operation in the Bacillus Calmette Guerin-induced activation of gammadelta T cells. Immunol Cell Biol 2013; 91:461-8; PMID:23797069; http://dx.doi.org/10.1038/icb.2013.30
72. D.W.Fowler, J.Copier, N.Wilson, A.G.Dalgleish, M.D.Bodman-Smith. Mycobacteria activate gammadelta T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother 2012; 61:535-47; PMID:22002242; http://dx.doi.org/10.1007/s00262-011-1121-4
73. I.Sanseverino, C.Purificato, B.Varano, L.Conti, S.Gessani, M.C.Gauzzi. STAT3-silenced human dendritic cells have an enhanced ability to prime IFNgamma production by both alphabeta and gammadelta T lymphocytes. Immunobiology 2014; 219:503-11; PMID:24674241; http://dx.doi.org/10.1016/j.imbio.2014.02.012
74. C.Collins, J.Wolfe, K.Roessner, C.Shi, L.H.Sigal, R.C.Budd. Lyme arthritis synovial gammadelta T cells instruct dendritic cells via fas ligand. J Immunol 2005; 175:5656-65; PMID:16237055; http://dx.doi.org/10.4049/jimmunol.175.9.5656
75. L.Conti, R.Casetti, M.Cardone, B.Varano, A.Martino, F.Belardelli, F.Poccia, S.Gessani. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 2005; 174:252-60; PMID:15611247; http://dx.doi.org/10.4049/jimmunol.174.1.252
76. J.R.Gordon, Y.Ma, L.Churchman, S.A.Gordon, W.Dawicki. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol 2014; 5:7; PMID:24550907; http://dx.doi.org/10.3389/fimmu.2014.00007
77. T.Kitawaki, N.Kadowaki, K.Fukunaga, Y.Kasai, T.Maekawa, K.Ohmori, T.Kondo, R.Maekawa, M.Takahara, M.Nieda et al. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. Brit J Haematol 2011; 153:796-9; PMID:21477159; http://dx.doi.org/10.1111/j.1365-2141.2010.08490.x
78. A.A.Dar, R.S.Patil, S.V.Chiplunkar. Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses. Front Immunol 2014; 5:366; PMID:25132835; http://dx.doi.org/10.3389/fimmu.2014.00366
79. J.C.Ribot, S.T.Ribeiro, D.V.Correia, A.E.Sousa, B.Silva-Santos. Human gammadelta thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2/IL-15 signaling. J Immunol 2014; 192:2237-43; PMID:24489097; http://dx.doi.org/10.4049/jimmunol.1303119